BackBUSINESS
Dr Reddy's Granted Health Canada Approval to Sell Generic Ozempic (Semaglutide)
Health Canada approved Dr Reddy's semaglutide injection, making it the first generic Ozempic in Canada and the first G7 country to clear a semaglutide generic. The move follows patent expiry earlier in 2026, with expectations of lower prices and increased access, potentially triggering a broader price competition in GLP-1 therapies.
Why It Matters
If generics lower prices, access to GLP-1 therapies could improve for diabetes and weight-management patients, while competition may push costs downward across markets.
Timeline
2 Events
Health Canada approves Dr Reddy's generic Ozempic (semaglutide)
April 29, 2026
Health Canada authorised Dr Reddy's semaglutide injection after a full review of safety, efficacy and quality; the approval covers the same once-weekly treatment for Type-2 diabetes as the branded Ozempic; Canada becomes the first G7 country to clear a generic semaglutide product.
Canada patent expiry clears path for generic semaglutide
2026
Patent protections on semaglutide expired in Canada, opening the door for generic competition in the market.